Rev Esp Quimioter 2023;36(Suppl.1):54-58
Present and future of resistance in Pseudomonas aeruginosa: implications for treatment
MANUEL PINA-SÁNCHEZ, MARTA RUA, JOSÉ LUIS DEL POZO
Published: 24 November 2023
http://www.doi.org/10.37201/req/s01.13.2023
ABSTRACT
Pseudomonas aeruginosa is a pathogen that has a high propensity to develop antibiotic resistance, and the emergence of multidrug-resistant strains is a major concern for global health. The mortality rate associated with infections caused by this microorganism is significant, especially those caused by multidrug-resistant strains. The antibiotics used to treat these infections include quinolones, aminoglycosides, colistin, and β-lactams. However, novel combinations of β-lactams-β-lactamase inhibitors and cefiderocol offer advantages over other members of their family due to their better activity against certain resistance mechanisms.
Selecting the appropriate empiric antibiotic treatment requires consideration of the patient’s clinical entity, comorbidities, and risk factors for multidrug-resistant pathogen infections, and local epidemiological data. Optimizing antibiotic pharmacokinetics, controlling the source of infection, and appropriate collection of samples are crucial for successful treatment.
In the future, the development of alternative treatments and strategies, such as antimicrobial peptides, new antibiotics, phage therapy, vaccines, and colonization control, holds great promise for the management of P. aeruginosa infections.
Rev Esp Quimioter 2023; 36(Suppl.1):54-58 [Full-text PDF]
